Business
Kazia (ASX:KZA) share price slides despite positive update
The Kazia Therapeutics Ltd (ASX: KZA) share price is backtracking today despite announcing encouraging data from its paxalisib phase II study. At the time of writing, the biotech company’s shares are fetching $1.81, down 3.72%.
What did Kazia update the ASX with?
Investors appear unfazed by the company’s latest release, sending Kazia shares lower.
In its announcement, Kazia shared some key points of its ongoing phase II study of paxalisib in glioblastoma – a common and very aggressive type of brain cancer.
They are as follows:
- Pharmacokinetic (PK) data which shows how long paxalisib remains in the human body, strongly supports 60 milligrams…
-
General17 hours agoByford rail extension opening marks final stage of Perth Metronet
-
Noosa News23 hours agoFatal traffic crash, Baringa – Sunshine Coast
-
General19 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery
-
Business21 hours agoWhat $10,000 invested in the iShares S&P 500 IVV ETF could be in 10 years